Lamivudine; zidovudine - Generic Drug Details

What are the generic sources for lamivudine; zidovudine and what is the scope of freedom to operate?

Lamivudine; zidovudine is the generic ingredient in two branded drugs marketed by Viiv Hlthcare, Aurobindo Pharma, Aurobindo Pharma Ltd, Chartwell Rx, Cipla, Epic Pharma Llc, Hetero Labs Ltd Iii, Hetero Labs Ltd V, Lupin Ltd, Macleods Pharms Ltd, Natco, Pharmacare, and Pharmobedient, and is included in fourteen NDAs. Additional information is available in the individual branded drug profile pages.

Eight suppliers are listed for this compound. There are thirteen tentative approvals for this compound.

Summary for lamivudine; zidovudine

US Patents:	0
Tradenames:	2
Applicants:	13
NDAs:	14
Finished Product Suppliers / Packagers:	8
Raw Ingredient (Bulk) Api Vendors:	5
Clinical Trials:	188
DailyMed Link:	lamivudine; zidovudine at DailyMed

Recent Clinical Trials for lamivudine; zidovudine

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
The Aurum Institute NPC	Phase 1/Phase 2
Johns Hopkins University	Phase 1/Phase 2
Wellcome Trust	Phase 2

See all lamivudine; zidovudine clinical trials

Generic filers with tentative approvals for LAMIVUDINE; ZIDOVUDINE

Applicant	Application No.	Strength	Dosage Form
		150MG; 300MG; 600MG	TABLET; ORAL
		150MG; 300MG; 300MG	TABLET; ORAL
		150MG; 300MG; 200MG	TABLET; ORAL

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Pharmacology for lamivudine; zidovudine

Drug Class	Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor
Mechanism of Action	Nucleoside Reverse Transcriptase Inhibitors

Anatomical Therapeutic Chemical (ATC) Classes for lamivudine; zidovudine

J05AF	Nucleoside and nucleotide reverse transcriptase inhibitors
J05A	DIRECT ACTING ANTIVIRALS
J05	ANTIVIRALS FOR SYSTEMIC USE
J	Antiinfectives for systemic use

J05AF	Nucleoside and nucleotide reverse transcriptase inhibitors
J05A	DIRECT ACTING ANTIVIRALS
J05	ANTIVIRALS FOR SYSTEMIC USE
J	Antiinfectives for systemic use

US Patents and Regulatory Information for lamivudine; zidovudine

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Hetero Labs Ltd V	LAMIVUDINE AND ZIDOVUDINE	lamivudine; zidovudine	TABLET;ORAL	203259-001	Feb 3, 2014	AB	RX	No	No
Viiv Hlthcare	COMBIVIR	lamivudine; zidovudine	TABLET;ORAL	020857-001	Sep 26, 1997		DISCN	Yes	No
Pharmobedient	LAMIVUDINE AND ZIDOVUDINE	lamivudine; zidovudine	TABLET;ORAL	079079-001	Aug 12, 2019		DISCN	No	No

Expired US Patents for lamivudine; zidovudine

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Viiv Hlthcare	COMBIVIR	lamivudine; zidovudine	TABLET;ORAL	020857-001	Sep 26, 1997	4,724,232*PED
Viiv Hlthcare	COMBIVIR	lamivudine; zidovudine	TABLET;ORAL	020857-001	Sep 26, 1997	6,180,639*PED
Viiv Hlthcare	COMBIVIR	lamivudine; zidovudine	TABLET;ORAL	020857-001	Sep 26, 1997	5,047,407*PED

EU/EMA Drug Approvals for lamivudine; zidovudine

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Teva Pharma B.V.	Lamivudine/Zidovudine Teva	lamivudine, zidovudine	EMEA/H/C/001236Lamivudine/Zidovudine Teva is indicated in antiretroviral combination therapy for the treatment of human-immunodeficiency-virus (HIV) infection.	Withdrawn	yes	no	no	2011-02-28
ViiV Healthcare BV	Combivir	lamivudine, zidovudine	EMEA/H/C/000190Combivir is indicated in antiretroviral combination therapy for the treatment of Human Immunodeficiency Virus (HIV) infection.,	Authorised	no	no	no	1998-03-18

Market Dynamics and Financial Trajectory for Lamivudine; Zidovudine

Last updated: February 20, 2026

What is the current market landscape for Lamivudine and Zidovudine?

Lamivudine and Zidovudine are antiretroviral drugs primarily used for HIV treatment. Their combined formulations, often as fixed-dose combinations (FDCs), have remained standard in HIV management.

The global HIV drug market totaled approximately USD 21.5 billion in 2022 and is expected to reach USD 29 billion by 2027, growing at a compound annual growth rate (CAGR) of 6.8% (Statista, 2023). Lamivudine and Zidovudine account for a significant portion of this market, especially in regions relying on generic formulations.

Key players include Gilead Sciences, Mylan, and Cipla, producing both branded and generic versions. The market is strongly influenced by patent expirations, regulatory landscapes, and shifts toward integrase inhibitors and other newer therapies.

What are the drivers and inhibitors affecting the market?

Drivers

• Patent expirations: Major patents on combination formulations have expired since 2018, fueling generic competition and price reductions.
• Expanding access in emerging markets: Increased HIV testing and treatment programs in Africa and Asia boost demand for affordable generics.
• Healthcare policy shifts: Governments prioritize broad access to antiretrovirals, fostering procurement channels.
• Stable efficacy profile: Long-established safety and effectiveness provide continued demand.

Inhibitors

• Competition from newer drugs: Integrase inhibitors (e.g., Dolutegravir) are replacing Zidovudine/Lamivudine in first-line regimens due to better tolerability and efficacy.
• Regulatory hurdles: Stringent approval processes and evolving biosimilar and generic regulations impact market entry.
• Pricing pressures: Government and payer policies enforce price caps, reducing margins.
• Discontinuation risk: Phasing out older drugs in favor of newer modalities could diminish market share.

How does the financial trajectory look for Lamivudine and Zidovudine?

Revenue trends

Following patent expirations, revenues for branded formulations declined sharply. In the US, Gilead's Zilulf (Lamivudine) sales fell by approximately 65% from 2018 to 2022, attributed to generic competition and market saturation.

Global sales for fixed-dose combinations containing Lamivudine and Zidovudine were estimated at USD 2.3 billion in 2022, decreasing from USD 3.1 billion in 2020. The decline reflects shift toward newer drug classes and market saturation.

Price erosion

Market entry of generics led to a 70-80% decrease in unit prices for branded formulations from 2018 to 2022. The average wholesale price (AWP) for a standard 30-day supply of the combination dropped from USD 150 to USD 30 over this period.

Future projections

By 2027, revenues are expected to decline further to approximately USD 1 billion, driven by:

• Continued preference for integrase inhibitors.
• Lowered drug prices due to generic proliferation.
• Potential phase-out in high-income markets.

In contrast, volume sales may stabilize or slightly grow in low-income countries due to expanding HIV treatment access.

How do regulatory policies influence market and financial outcomes?

• Patent litigations and extensions: Delay generic entry in some regions.
• Regulatory approval pathways: Harmonization enables faster approval of generics, increasing competition.
• Tendering and procurement policies: Governments favor lowest-cost generics, suppressing margins.
• Inclusion in Essential Medicines Lists: Ensures steady demand in emerging markets.

How do manufacturing and supply chain factors impact the market?

• Global manufacturing capacity: Surge in generic production from India and China supports price declines.
• Supply chain disruptions: COVID-19 impacted availability and pricing stability, but recent recovery supports supply.
• Quality standards: Regulatory stringency ensures safety but can delay market entry.

Summary table of key data points

Metric	2018	2022	2027 (projected)
Global revenue (USD billion)	3.1	2.3	1.0
Average wholesale price (USD per 30-day supply)	150	30	20
Generic market share	~70%	>85%	>90%
Market growth rate (volume)	Stable	Slight decline	Stabilization or mild growth in emerging markets

Key insights

• The initial dominance of branded fixed-dose combinations is waning.
• Market consolidation through generics suppresses prices.
• Switching to newer drug classes constrains revenue.
• Low-income countries sustain demand due to essential medicine status.
• Patent expirations continue to accelerate generic penetration.

Key takeaways

Lamivudine and Zidovudine face declining revenues driven by patent expirations and market shifts to newer therapies. While revenues decline in developed markets, demand persists in emerging regions, bolstered by procurement policies favoring affordability. Future growth hinges on the ability of manufacturers to adapt to evolving treatment guidelines and competitive pressures.

FAQs

1. Will Lamivudine and Zidovudine disappear from the market?

Not entirely. They will likely remain in use in low-income regions and as second-line options, but their market share will diminish in favor of newer drugs.

2. How do patent expirations influence availability?

Patent expirations enable generic manufacturers to enter markets, increasing supply, reducing prices, and lowering revenue for branded versions.

3. Are generics equivalent to branded formulations?

Yes, approved generics must meet regulatory standards ensuring bioequivalence and safety.

4. What role do regulatory policies play?

Regulatory policies facilitate or hinder generic market entry, impacting prices and supply stability.

5. What are the prospects for revenue recovery?

Limited in developed markets due to preference for newer therapies. Stable or modest growth possible in emerging markets due to ongoing treatment access expansion.

---

References

[1] Statista. (2023). Global HIV drug market size and forecast. https://www.statista.com

[2] Gilead Sciences Annual Reports. (2018–2022). Revenue breakdown by drugs. https://www.gilead.com

[3] WHO. (2022). HIV treatment guidelines and essential medicines. https://www.who.int

[4] IMS Health. (2021). Anti-retroviral drug market analysis. https://www.imshealth.com